Merck & Co Inc (MRK): Health Care's Featured Stock Of The Day

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Merck ( MRK) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.3%. By the end of trading, Merck rose $1.33 (2.9%) to $46.84 on average volume. Throughout the day, 18.6 million shares of Merck exchanged hands as compared to its average daily volume of 16.7 million shares. The stock ranged in a price between $45.78-$46.97 after having opened the day at $45.91 as compared to the previous trading day's close of $45.51. Other companies within the Health Care sector that increased today were: Star Scientific ( STSI), up 14.8%, OxiGene ( OXGN), up 14.2%, BioTime ( BTX), up 12.6%, and Spherix ( SPEX), up 12.2%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $137.46 billion and is part of the drugs industry. The company has a P/E ratio of 22.7, above the S&P 500 P/E ratio of 17.7. Shares are up 11.2% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Merck a buy, one analyst rates it a sell, and four rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Synergy Pharmaceuticals ( SGYP), down 17%, Harvard Bioscience ( HBIO), down 13.6%, iBio ( IBIO), down 9.2%, and Infinity Pharmaceuticals ( INFI), down 9%, were all laggards within the health care sector with Health Management Associates ( HMA) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.

null

More from Markets

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Video: Stop Using Student Loan Money to Buy Bitcoin

Video: Stop Using Student Loan Money to Buy Bitcoin

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Facebook Sends Facial Recognition Notification in Error

Facebook Sends Facial Recognition Notification in Error